RO5093151

Phase 2Small molecule

Roche

RO5093151 is one of 94 small molecule programs targeting Non-Alcoholic Fatty Liver Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Alcoholic Fatty Liver DiseaseActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Ocular HypertensionActive, not recruiting

Non-Alcoholic Fatty Liver DiseasePhase 1

Active, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Ocular HypertensionPhase 1

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Tanzeum

GSK

Preclinical

10 2

Insulin 320

Novo Nordisk

Preclinical

43 3

NOVOLIN R

Novo Nordisk

Preclinical

1 4

RO5093151

Roche

Phase 2

1 5

Dostinex

Golytely

Myrbetriq

Lantus

6 9

Lixisenatide

Sanofi

Preclinical

4 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ocular Hypertension2 trials

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

Completed· Roche logo

Roche·Phase 1·NCT02622334·45 enrolled

A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma

Completed· Roche logo

Roche·Phase 2·NCT01493271·31 enrolled

Interaction1 trial

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01591850·51 enrolled

Type 2 Diabetes Mellitus1 trial

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

Completed· Roche logo

Roche·Phase 2·NCT00823680·110 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease

Completed· Roche logo

Roche·Phase 1·NCT01277094·82 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for RO5093151. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RO5093151 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RO5093151. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Roche

RO5093151

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ocular Hypertension2 trials

Interaction1 trial

Type 2 Diabetes Mellitus1 trial

Non-Alcoholic Fatty Liver Disease1 trial

References

Drug Info

Quick Facts

Related News